Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07457918) titled 'Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)' on Feb. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Verrica Pharmaceuticals Inc.
Condition:
Common Warts (Verruca Vulgaris)
Common Warts
Human Papilloma Virus (HPV)
Warts
Intervention:
Combination Product: Cantharidin
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 2026
Target Sample Size: 600
Countries of Recruitment:
U...